AbstractThe need for an effective vaccine to prevent the global spread of human immunodeficiency virus type 1 (HIV-1) is well recognized. Passive immunization and challenge studies in non-human primates testify that broadly neutralizing antibodies (BrNAbs) can accomplish protection against infection. In recent years, the introduction of new techniques has facilitated the discovery of an unprecedented number of new human BrNAbs that target and delineate diverse conserved epitopes on the envelope glycoprotein spike (Env). The epitopes of these BrNAbs can serve as templates for immunogen design aimed to induce similar antibodies. Here we will review the characteristics of the different classes of BrNAbs and their target epitopes, as well as fa...
The HIV-1 envelope glycoprotein (Env) trimer is the key target for vaccines aimed at inducing neutra...
A primary correlate of protection for most effective viral vaccines is induction of antibodies with ...
AbstractNeutralizing antibody (nAb) response is sporadic and has limited potency and breadth during ...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
After over 35 years of research, a prophylactic HIV vaccine remains elusive. However, the discovery ...
Abstract Broadly neutralizing antibodies (bNAbs), able to prevent viral entry by diverse global viru...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are b...
Abstract Despite enormous efforts no HIV-1 vaccine has been developed that elicits broadly neutraliz...
Introduction: Despite intensive research efforts, there is still no effective prophylactic vaccine a...
Neutralizing antibodies can protect from infection by immunodeficiency viruses. However, the inducti...
A current strategy for the design of neutralizing antibody-based vaccines to prevent HIV-1 transmiss...
Abstract A large array of broadly neutralizing antibodies (bnAbs) against HIV have been isolated and...
SummaryBroadly neutralizing HIV antibodies are much sought after (a) to guide vaccine design, both a...
The HIV-1 envelope glycoprotein (Env) trimer is the key target for vaccines aimed at inducing neutra...
A primary correlate of protection for most effective viral vaccines is induction of antibodies with ...
AbstractNeutralizing antibody (nAb) response is sporadic and has limited potency and breadth during ...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
After over 35 years of research, a prophylactic HIV vaccine remains elusive. However, the discovery ...
Abstract Broadly neutralizing antibodies (bNAbs), able to prevent viral entry by diverse global viru...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are b...
Abstract Despite enormous efforts no HIV-1 vaccine has been developed that elicits broadly neutraliz...
Introduction: Despite intensive research efforts, there is still no effective prophylactic vaccine a...
Neutralizing antibodies can protect from infection by immunodeficiency viruses. However, the inducti...
A current strategy for the design of neutralizing antibody-based vaccines to prevent HIV-1 transmiss...
Abstract A large array of broadly neutralizing antibodies (bnAbs) against HIV have been isolated and...
SummaryBroadly neutralizing HIV antibodies are much sought after (a) to guide vaccine design, both a...
The HIV-1 envelope glycoprotein (Env) trimer is the key target for vaccines aimed at inducing neutra...
A primary correlate of protection for most effective viral vaccines is induction of antibodies with ...
AbstractNeutralizing antibody (nAb) response is sporadic and has limited potency and breadth during ...